CORBUS PHARMACEUTICALS HLDGS ($CRBP) posted quarterly earnings results for Q4 2025 on Monday, March 9th. The company reported earnings of -$1.25 per share, beating estimates of -$1.61 by $0.36. The company also reported revenue of $0, missing estimates of $1,700,003 by $-1,700,003.
You can see Quiver Quantitative's $CRBP stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CORBUS PHARMACEUTICALS HLDGS Insider Trading Activity
CORBUS PHARMACEUTICALS HLDGS insiders have traded $CRBP stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $CRBP stock by insiders over the last 6 months:
- YUVAL COHEN (Chief Executive Officer) has made 0 purchases and 2 sales selling 27,633 shares for an estimated $471,203.
- SEAN F. MORAN (Chief Financial Officer) sold 12,981 shares for an estimated $220,936
- DOMINIC SMETHURST (Chief Medical Officer) sold 3,285 shares for an estimated $26,574
- ANNE ALTMEYER sold 1,060 shares for an estimated $21,730
- IAN HODGSON (Chief Operating Officer) sold 2,415 shares for an estimated $19,537
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CORBUS PHARMACEUTICALS HLDGS Hedge Fund Activity
We have seen 51 institutional investors add shares of CORBUS PHARMACEUTICALS HLDGS stock to their portfolio, and 44 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ABERDEEN GROUP PLC added 1,133,519 shares (+602.2%) to their portfolio in Q4 2025, for an estimated $9,226,844
- CITADEL ADVISORS LLC added 843,193 shares (+inf%) to their portfolio in Q4 2025, for an estimated $6,863,591
- ORBIMED ADVISORS LLC added 425,000 shares (+36.3%) to their portfolio in Q4 2025, for an estimated $3,459,500
- STONEPINE CAPITAL MANAGEMENT, LLC added 389,916 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,173,916
- ARMISTICE CAPITAL, LLC added 344,000 shares (+179.2%) to their portfolio in Q4 2025, for an estimated $2,800,160
- PROSIGHT MANAGEMENT, LP added 340,472 shares (+99.1%) to their portfolio in Q4 2025, for an estimated $2,771,442
- ADAR1 CAPITAL MANAGEMENT, LLC added 276,581 shares (+2711.6%) to their portfolio in Q4 2025, for an estimated $2,251,369
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CORBUS PHARMACEUTICALS HLDGS Analyst Ratings
Wall Street analysts have issued reports on $CRBP in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 11/13/2025
- Wedbush issued a "Outperform" rating on 10/20/2025
To track analyst ratings and price targets for CORBUS PHARMACEUTICALS HLDGS, check out Quiver Quantitative's $CRBP forecast page.
CORBUS PHARMACEUTICALS HLDGS Price Targets
Multiple analysts have issued price targets for $CRBP recently. We have seen 3 analysts offer price targets for $CRBP in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Brian Abrahams from RBC Capital set a target price of $53.0 on 11/13/2025
- Andres Y. Maldonado from HC Wainwright & Co. set a target price of $40.0 on 10/20/2025
- Robert Driscoll from Wedbush set a target price of $38.0 on 10/20/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
